Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
502487-67-4CC(C)=CCC/C(C)=C/CNCCNC1C2CC3CC(C2)CC1C3JFIBVDBTCDTBRH-REZTVBANSA-NSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
VerwendenSQ109 has been used: as an antitubercularagent to study its interactions with mycobacterial membrane proteins large 3 (MmpL3) binding pocket as a positive control to determine the minimum inhibitory concentration (MIC) of ohmyungsamycins (OMS) A and B against Mycobacterium tuberculosis(Mtb) using the resazurin microtiter assay (REMA) plate method as an inhibitor of MmpL3 to explore the utility of mycobacterial CRISPR interference for validating target gene essentiality and compound mode of action
502487-67-4DTXSID30964540CHEMBL561057